News
The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback